A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers.
Epidemiology
RNA vaccines
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
07
2021
accepted:
15
12
2021
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Nursing home (NH) residents have been severely affected during the COVID-19 pandemic because of their age and underlying comorbidities. Infection and outbreaks in NHs are most likely triggered by infected workers. Screening for asymptomatic NH workers can prevent risky contact and viral transmission to the residents. This study examined the effect of the BNT162b2 mRNA COVID‑19 (Comirnaty A 2-month cohort study was conducted among 99 NHs in the Walloon region (Belgium), at the start of February 2021. Three groups of workers, i.e., non-vaccinated ( The protection fraction against the excretion of the SARS-CoV-2 in the saliva samples of the workers after the second dose is estimated at 0.90 (95% CI: 0.18; 0.99) at 1 week and 0.83 (95% CI: 0.54; 0.95) at 8 weeks. We observe more circulating SARS-CoV-2 and a greater variability of viral loads in the unvaccinated group compared to those of the vaccinated group. This field cohort study advances our knowledge of the efficacy of the mRNA BNT162b2 COVID-19 vaccine on the viral shedding in the saliva specimens of vaccinated NH workers, contributing to better decision-making in public health interventions and management.
Sections du résumé
Background
UNASSIGNED
Nursing home (NH) residents have been severely affected during the COVID-19 pandemic because of their age and underlying comorbidities. Infection and outbreaks in NHs are most likely triggered by infected workers. Screening for asymptomatic NH workers can prevent risky contact and viral transmission to the residents. This study examined the effect of the BNT162b2 mRNA COVID‑19 (Comirnaty
Methods
UNASSIGNED
A 2-month cohort study was conducted among 99 NHs in the Walloon region (Belgium), at the start of February 2021. Three groups of workers, i.e., non-vaccinated (
Results
UNASSIGNED
The protection fraction against the excretion of the SARS-CoV-2 in the saliva samples of the workers after the second dose is estimated at 0.90 (95% CI: 0.18; 0.99) at 1 week and 0.83 (95% CI: 0.54; 0.95) at 8 weeks. We observe more circulating SARS-CoV-2 and a greater variability of viral loads in the unvaccinated group compared to those of the vaccinated group.
Conclusions
UNASSIGNED
This field cohort study advances our knowledge of the efficacy of the mRNA BNT162b2 COVID-19 vaccine on the viral shedding in the saliva specimens of vaccinated NH workers, contributing to better decision-making in public health interventions and management.
Identifiants
pubmed: 35603280
doi: 10.1038/s43856-021-00067-3
pii: 67
pmc: PMC9053279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsF.B. and L.G. are the inventors of the device used in the saliva collection kit. This device was patented (EP20186086.3) and produced by Diagenode (Seraing, Belgium) under a commercial agreement with the University of Liège. This does not alter the adherence to all journal policies on sharing data and materials, as detailed online in the Author Guide. All other authors do not have competing interests.
Références
Drugs. 2021 Mar;81(4):495-501
pubmed: 33683637
Transbound Emerg Dis. 2021 Aug 6;:
pubmed: 34357691
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Medicine (Baltimore). 2020 Dec 18;99(51):e23547
pubmed: 33371079
Lancet Reg Health Eur. 2021 Aug;7:100150
pubmed: 34250518
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Lancet Reg Health Eur. 2021 May;4:100056
pubmed: 33997830
Nat Med. 2021 May;27(5):892-903
pubmed: 33767405
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
Sci Rep. 2021 Jul 30;11(1):15729
pubmed: 34330988
Biol Methods Protoc. 2020 Jul 18;5(1):bpaa014
pubmed: 33029559
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Lancet Infect Dis. 2020 Nov;20(11):1233-1234
pubmed: 32679088
Lancet Infect Dis. 2020 Nov;20(11):1231-1232
pubmed: 32530425
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Infect Dis Now. 2021 Mar;51(2):197-200
pubmed: 33521774
Front Med (Lausanne). 2020 Aug 04;7:465
pubmed: 32903849
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Vaccines (Basel). 2021 Apr 01;9(4):
pubmed: 33915829
Infect Dis Poverty. 2020 Jul 22;9(1):100
pubmed: 32698862
Infect Dis Poverty. 2020 Jun 22;9(1):72
pubmed: 32564770
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381
pubmed: 32240128
R Soc Open Sci. 2017 Feb 1;4(2):160254
pubmed: 28386409
Bol Med Hosp Infant Mex. 2021;78(1):66-74
pubmed: 33662986
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
PLoS One. 2021 Mar 11;16(3):e0247773
pubmed: 33705435
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Commun. 2021 May 25;12(1):3109
pubmed: 34035301